Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
J Antimicrob Chemother ; 59(1): 35-42, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17079241

ABSTRACT

OBJECTIVES: Disease caused by penicillin-resistant Streptococcus pneumoniae (PRSP) is associated with more suppurative complications than disease caused by penicillin-susceptible S. pneumoniae (PSSP). Exposure of S. pneumoniae to beta-lactam antibiotics enhances the proinflammatory activation of human cells by pneumococci via Toll-like receptor-2 (TLR2). To test the hypothesis that penicillin resistance influences cellular TLR2 activation by beta-lactam-exposed pneumococci, we compared TLR2 induction by PSSP (MIC 0.06 mg/L) and a high-level PRSP clinical isolate (159; MIC 16 mg/L) following exposure to penicillin and cefotaxime. METHODS: Both organisms were treated with penicillin or cefotaxime at and around the MIC. TLR2 signalling was measured as relative IL-8 promoter activation in transfected HeLa cells. RESULTS: On exposure to penicillin, log-phase PSSP and PRSP induced TLR2-proinflammatory activation at levels significantly higher than unexposed bacteria, and maximal in each case at the MIC. Transformants containing low-affinity penicillin-binding proteins (PBP) 2x, 1a and 2b exhibited stepwise resistance to cefotaxime and penicillin. TLR2 activation following penicillin treatment was dependent on an abnormal cell wall (PBP1a and 2x) and autolysis (PBP2b). High affinity PBP2x was required for this effect to be observed in log-phase pneumococci exposed to cefotaxime at the MIC. Cefotaxime-mediated TLR2 activation was not observed in lag-phase transformants exposed to sub-lethal concentrations. CONCLUSIONS: These data show that PRSP have similar TLR2-proinflammatory effects to PSSP when exposed to beta-lactam antibiotics but the antibiotic concentration relative to the MIC is critical. This has implications for treatment of pneumococcal disease when tissue concentrations of antibiotic are close to the MIC.


Subject(s)
Anti-Bacterial Agents/pharmacology , Penicillin Resistance , Streptococcus pneumoniae/drug effects , Toll-Like Receptor 2/physiology , beta-Lactams/pharmacology , Cefotaxime/pharmacology , HeLa Cells , Humans , Lipopolysaccharide Receptors/physiology , Microbial Sensitivity Tests , Penicillin-Binding Proteins/metabolism , Penicillins/pharmacology
2.
Microbes Infect ; 8(7): 1732-40, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16815071

ABSTRACT

Neurocysticercosis, infection with larval Taenia solium, is a common, serious neuroparasitic infection. Larval degeneration results in inflammatory cell influx and granuloma formation which leads to clinical symptomatology. The role of chemokines in such cell influx is unknown. We demonstrate that monocyte stimulation by T. solium larval antigen (TsAg) results in a differential profile of CXCL8/IL-8 (146.5+/-8.5ng/ml after 24h), CCL2/MCP-1 (267+/-4 ng/ml after 48 h) and CCL3/MIP-1alpha (1.72+/-0.43 ng/ml after 8 h) secretion. There was coordinate mRNA accumulation reaching maximum at 1h for CCL3 and 2 h for CXCL8 and CCL2. TsAg induced maximal nuclear binding of p65, p50 and c-rel subunits of the transcriptional regulator NF-kappaB by 2 h. IkappaBalpha but not IkappaBbeta was degraded within 10 min before resynthesis by 2 h. Pre-treatment with the broad-spectrum NF-kappaB inhibitor pyrrolidine dithiocarbamate caused complete abrogation of TsAg-induced CCL2 secretion (p=0.005) and 91% reduction of CXCL8 secretion (p=0.0003). TsAg was unable to induce CXCL8 promoter activity in Toll-like receptor (TLR)-2 or TLR-4/MD-2 transfected HeLa cells in the absence of lectins or other adaptor molecules. In summary, our data demonstrate that TsAg induces chemokine secretion via specific pathways dependent on NF-kappaB but not TLR-4/TLR-2, and indicate a potential mechanism whereby larval degeneration results in brain inflammation.


Subject(s)
Antigens, Helminth/immunology , Chemokines/metabolism , Cysticercus/immunology , Monocytes/immunology , NF-kappa B p50 Subunit/metabolism , Transcription Factor RelA/metabolism , Animals , Cell Nucleus/chemistry , Cells, Cultured , Chemokine CCL2/metabolism , Chemokines/genetics , Chemokines, CXC/genetics , Chemokines, CXC/metabolism , Gene Expression , Humans , I-kappa B Proteins/metabolism , Interleukin-8/biosynthesis , Monocytes/metabolism , NF-KappaB Inhibitor alpha , NF-kappa B/antagonists & inhibitors , Pyrrolidines/pharmacology , RNA, Messenger/analysis , RNA, Messenger/genetics , Swine , Thiocarbamates/pharmacology , Toll-Like Receptors/physiology
3.
Int J Antimicrob Agents ; 26(3): 188-96, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16099623

ABSTRACT

beta-Lactam antibiotics cause release of pro-inflammatory bacterial cell wall structures. We determined the effect of penicillin treatment of Streptococcus pneumoniae on the induction of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) genes by human macrophages and the influence of antibiotic concentration and bacterial growth phase upon this induction. Gene expression was measured by real-time polymerase chain reaction (PCR) and protein was measured by enzyme-linked immunosorbent assay (ELISA). Treatment of lag phase S. pneumoniae with one-eighth minimum inhibitory concentration (MIC) penicillin resulted in enhanced expression of TNF-alpha messenger RNA (mRNA), but not TNF-alpha protein at 6h compared with untreated bacteria. IL-1beta mRNA and protein were not affected by these bacteria. MIC treatment of lag or early log phase bacteria induced both protein and mRNA for IL-1beta. Bacteria exposed to concentrations of penicillin that cause lysis (MIC) or no lysis with morphological changes (sub-MIC) induce differential patterns of pro-inflammatory cytokine expression by human macrophages.


Subject(s)
Cytokines/metabolism , Macrophages/immunology , Penicillins/pharmacology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/immunology , Anti-Bacterial Agents/pharmacology , Cells, Cultured , Cytokines/genetics , Enzyme-Linked Immunosorbent Assay , Gene Expression , Humans , Interleukin-1/genetics , Interleukin-1/metabolism , Microbial Sensitivity Tests , Microscopy, Electron, Scanning , Polymerase Chain Reaction , RNA, Messenger/analysis , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
4.
J Antimicrob Chemother ; 54(1): 76-8, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15190028

ABSTRACT

OBJECTIVES: The exposure of Streptococcus pneumoniae to cell-wall-active antibiotics in vivo and in vitro results in the release of bacterial components that can induce proinflammatory activation of human cells via toll-like receptor 2 (TLR2). The aim of this study was to compare the activation of human TLR2 pathways after exposure of S. pneumoniae to faropenem, cefotaxime and vancomycin. MATERIALS AND METHODS: Streptococcus pneumoniae D39 was exposed to cefotaxime, faropenem or vancomycin for 6 h during lag or early log phase growth. IL-8 promoter activity of HeLa cells was measured using a dual luciferase reporter plasmid system. HeLa cells were transfected with an expression vector containing TLR2/CD14, or empty vector/CD14 and IL-8 promoter activity was measured using luminescence. Cells were stimulated with antibiotic-treated bacteria, untreated bacteria or medium-only controls. RESULTS: Lag phase S. pneumoniae treated at sub-MIC (1/8 MIC) cefotaxime or faropenem induced 11-fold and 8-fold increases, respectively, in TLR2-mediated IL-8 promoter activity when compared with untreated bacteria. Early log MIC cefotaxime or faropenem-treated bacteria also enhanced TLR2 activation by 3-fold and 4-fold, respectively, when compared with untreated bacteria. Vancomycin treatment had no effect on TLR2 induction at any growth stage or MIC ratio tested. CONCLUSIONS: beta-Lactam antibiotics induce surface changes and release of cell wall structures from bacteria that are proinflammatory via TLR2, but the glycopeptide vancomycin does not.


Subject(s)
Anti-Bacterial Agents/pharmacology , Membrane Glycoproteins/agonists , Receptors, Cell Surface/agonists , Streptococcus pneumoniae/physiology , Vancomycin/pharmacology , Cefotaxime/pharmacology , Cell Wall/drug effects , Cephalosporins/pharmacology , Genes, Reporter/genetics , HeLa Cells , Humans , Interleukin-8/biosynthesis , Interleukin-8/genetics , Lactams/pharmacology , Lipopolysaccharide Receptors/biosynthesis , Lipopolysaccharide Receptors/genetics , Luciferases/genetics , Microbial Sensitivity Tests , Plasmids/genetics , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/growth & development , Toll-Like Receptor 2 , Toll-Like Receptors , Transfection , beta-Lactams
5.
J Infect Dis ; 188(7): 1040-8, 2003 Oct 01.
Article in English | MEDLINE | ID: mdl-14513425

ABSTRACT

The Streptococcus pneumoniae cell-wall components peptidoglycan and lipoteichoic acid activate Toll-like receptor 2 (TLR2), which transduces an inflammatory response. After exposure to penicillin, type 2 S. pneumoniae strain D39, but not the isogenic autolysin-deficient mutant AL2, induced significantly enhanced interleukin-8 promoter activity in TLR2-transfected HeLa cells. Lag-phase D39 exhibited enhanced TLR2 activation after exposure to penicillin at levels below the minimum inhibitory concentration (MIC); in contrast, early log-phase S. pneumoniae were most active when exposed to the MIC. This enhancement was not ablated by heat treatment but was attenuated by autolysin inhibitors. The antimicrobial activity of moxifloxacin and erythromycin was not associated with TLR2 activation by S. pneumoniae. These data show that penicillin treatment of S. pneumoniae releases proinflammatory cell-wall components that activate TLR2 and that this activity is dependent on autolysin, the growth phase of the organism, and the antibiotic concentration.


Subject(s)
Aza Compounds , Fluoroquinolones , Membrane Glycoproteins/immunology , Penicillins/pharmacology , Pneumococcal Infections/immunology , Quinolines , Receptors, Cell Surface/immunology , Streptococcus pneumoniae/immunology , Anti-Infective Agents/pharmacology , Choline/pharmacology , Colony Count, Microbial , Enzyme Inhibitors/pharmacology , Erythromycin/pharmacology , Ethanolamine/pharmacology , HeLa Cells , Humans , Interleukin-8/immunology , Interleukin-8/metabolism , Moxifloxacin , N-Acetylmuramoyl-L-alanine Amidase/antagonists & inhibitors , N-Acetylmuramoyl-L-alanine Amidase/immunology , N-Acetylmuramoyl-L-alanine Amidase/metabolism , Pneumococcal Infections/drug therapy , Streptococcus pneumoniae/drug effects , Toll-Like Receptor 2 , Toll-Like Receptors , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL